Spark's Vision Loss Gene Therapy Raises US FDA Questions About Novel Endpoint

Multi-luminance mobility testing was developed by firm to measure functional vision across a range of lighting levels in patients with RPE65 mutations; advisory committee also will consider minimum patient age and clinical stage of disease appropriate for subretinal injections with voretigene.